NEW YORK (GenomeWeb News) – French biotech Genomic Vision today announced it and Quest Diagnostics have extended their strategic alliance agreement originally forged in 2011.

Under the terms of the extension, Quest will invest in the planned development of a laboratory-developed test for an undisclosed hereditary genetic disease. The two firms also will collaborate on automating the testing process and improving turnaround times for tests that use Genomic Vision's DNA combing technique.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.